Minister for Health announces commitment to improved access to lymphoedema compression garment subsidies
20 June 2018
In response to the State of the Nation report released by Breast Cancer Network of Australia on Wednesday 20 June, the Minister for Health, the Hon. Greg Hunt on behalf of the Australian Federal Government announced three commitments including: To work with state and territory governments to improve access to lymphoedema compression garment subsidies and create a national standard.
On Sunday 18 March 2018, the 3AW radio program 'Talking Health' with Dr Sally Cockburn focused their entire two hour broadcast to talking about lymphoedema. For those who were unable to listen to the broadcast, the podcast is now available.
Research Alert - Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up
30 October 2017
Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up
Ana Carolina Padula Ribeiro Pereira; Rosalina Jorge Koifman; Anke Bergmann
Highlights
•We followed a cohort of women surgically treated for breast cancer for 10 years.
•Incidence of lymphedema increases from 13.5% in two years to 41.1% in ten years.
•Radiotherapy, obesity, seroma, chemotherapy and stage were associated variables.
ABSTRACT
Purpose To evaluate the incidence and risk factors of lymphedema 10 years after surgical treatment for breast cancer.
Methods Prospective observational hospital-based cohort of women undergoing axillary lymph node dissection. Lymphedema was assessed by indirect volume, measured by circumference, and diagnosed if there was a difference of 200 mL between the arms or if the patient was treated for it. Independent variables were patient, tumour and treatment characteristics. Descriptive statistics were conducted as survival analysis using the Kaplan-Meier estimate. Cox regression was performed, considering a 95% confidence interval (95%CI).
Results The study evaluated 964 women. The cumulative incidence of lymphedema observed was 13.5% at two years of follow-up, 30.2% at five years and 41.1% at 10 years. Final model showed an increased risk for lymphedema among women that underwent radiotherapy (HR = 2.19; 95%CI 1.63–2.94), were obese (HR = 1.52; 95%CI 1.20–1.92), had seroma formation after surgery (HR = 1.46; 95%CI 1.14–1.87), underwent chemotherapy infusion in the affected limb (HR = 1.45; 95%CI 1.12–1.87) or advanced disease staging (HR = 1.41; 95%CI 1.11–1.80).
Conclusions Cumulative incidence of lymphedema was 41.1%. Women undergoing axillary radiotherapy, obese, who developed seroma, underwent chemotherapy infusion in the affected limb and with advanced disease had a higher risk of lymphedema.
ALA Industry Partners 2025
Exclusive Platinum Partner
Gold Partners
Silver Partners
Interested in becoming an ALA Industry Partner - click here for more information